 |
| Mark Capone, president of Myriad Genetic Laboratories |
Myriad Genetics ($MYGN) expanded its partnership with BioMarin Pharmaceutical ($BMRN) to use Myriad's myChoice HRD companion diagnostic test to identify which cancer patients are the best fit for BioMarin's talazoparib. The deal builds on an ongoing collaboration between the two companies, as BioMarin started using Myriad's BRACAnalysis CDx companion diagnostic test in 2013 in two clinical studies of the drug in breast cancer patients. Neither side is revealing financial terms for the expanded deal, but the companies will work together to push for regulatory approval for myChoice and talazoparib. "With cancer treatments, there is no one-size-fits-all approach for patients," Mark Capone, president of Myriad Genetic Laboratories, said in a statement. "We are excited to be working with BioMarin to help identify the patients who are most likely to benefit from talazoparib based on their own genetic makeup and biology." Statement